Sarepta Therapeutics (SRPT) Financials: History & Chart

Sarepta Therapeutics, Inc.(SRPT)

Biotechnology · Cambridge, MA

$17.31-0.18 (-1.03%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.

Cambridge, MA

835 employees

www.sarepta.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael E. Severino

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.97B	401.25M	730.80M	442.93M	399.36M	611.09M	744.86M	658.41M	467.17M
Cost of Goods Sold	818.23M	149.38M	119.36M	398.71M	150.78M	152.56M	137.56M	132.30M	91.69M
Gross Profit	1.16B	251.87M	611.44M	44.23M	248.58M	458.53M	607.29M	526.11M	375.48M
Gross Profit Margin	58.6%	62.8%	83.7%	10.0%	62.2%	75.0%	81.5%	79.9%	80.4%
Total Operating Expenses	1.30B	238.57M	253.01M	455.81M	351.97M	342.96M	907.68M	364.43M	353.29M
Research & Development	789.44M	91.26M	153.96M	325.34M	218.89M	204.39M	773.45M	199.95M	224.48M
Selling, General & Administrative	436.74M	107.60M	108.95M	128.30M	91.89M	137.90M	133.63M	163.87M	128.20M
Operating Income (EBIT)	-143.25M	13.29M	358.43M	-411.58M	-103.39M	115.58M	-300.39M	161.68M	22.20M
Operating Margin	-7.3%	3.3%	49.0%	-92.9%	-25.9%	18.9%	-40.3%	24.6%	4.8%
Income Before Tax (EBT)	-130.92M	-1.75M	343.17M	-278.30M	-194.05M	153.64M	-383.52M	171.74M	34.01M
Interest Income	29.97M	6.21M	7.00M	8.38M	8.38M	7.14M	12.43M	14.70M	18.33M
Interest Expense	58.35M	21.51M	21.71M	7.57M	7.57M	5.23M	4.50M	4.47M	4.92M
Other Income/Expense	12.33M	-15.04M	-15.26M	133.29M	-90.66M	38.06M	-83.13M	10.06M	11.81M
Net Income	-136.72M	-4.89M	330.96M	-282.85M	-179.95M	196.89M	-447.51M	159.05M	33.61M
Income Tax Expense	5.80M	3.14M	12.21M	4.55M	-14.10M	-43.25M	63.99M	12.69M	395K
Net Profit Margin	-6.9%	-1.2%	45.3%	-63.9%	-45.1%	32.2%	-60.1%	24.2%	7.2%
EBITDA	-98.54M	23.70M	369.03M	-406.33M	-84.94M	126.42M	-290.41M	172.14M	32.00M
EBITDA Margin	-5.0%	5.9%	50.5%	-91.7%	-21.3%	20.7%	-39.0%	26.1%	6.9%
Depreciation & Amortization	44.71M	10.41M	10.59M	5.25M	18.45M	10.84M	9.98M	10.46M	9.81M
EPS Basic	-1.44	-0.05	3.15	-2.74	-1.80	2.01	-4.60	1.65	0.35
EPS Diluted	N/A	-0.05	2.88	N/A	-1.80	1.89	-4.60	1.50	0.33
Weighted Average Basic Shares	105.43M	105.43M	104.99M	104.79M	100.24M	98.00M	97.36M	96.28M	95.39M
Weighted Average Diluted Shares	105.43M	105.43M	121.92M	104.79M	100.24M	106.62M	97.36M	108.47M	100.45M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	2.20B	1.90B	1.24B	933.01M	701.89M	540.10M	380.83M	301.03M
Cost of Goods Sold	881.50M	319.10M	150.34M	139.99M	97.05M	63.38M	56.59M	34.19M
Gross Profit	1.32B	1.58B	1.09B	793.02M	604.84M	476.72M	324.25M	266.84M
Gross Profit Margin	59.9%	83.2%	87.9%	85.0%	86.2%	88.3%	85.1%	88.6%
Total Operating Expenses	1.97B	1.36B	1.36B	1.33B	1.06B	1.04B	1.03B	610.47M
Research & Development	1.52B	804.52M	877.39M	877.09M	771.18M	722.34M	560.91M	401.84M
Selling, General & Administrative	478.94M	557.87M	481.87M	451.42M	282.66M	317.88M	284.81M	207.76M
Operating Income (EBIT)	-657.77M	218.08M	-267.82M	-536.20M	-459.71M	-564.16M	-705.56M	-343.63M
Operating Margin	-29.9%	11.5%	-21.5%	-57.5%	-65.5%	-104.5%	-185.3%	-114.1%
Income Before Tax (EBT)	-702.23M	260.77M	-520.10M	-689.96M	-418.95M	-553.07M	-713.88M	-362.61M
Interest Income	19.57M	71.77M	85.97M	27.72M	511K	2.97M	7.24M	6.81M
Interest Expense	9.73M	18.39M	22.01M	53.25M	63.52M	59.95M	30.67M	33.71M
Other Income/Expense	-44.45M	42.69M	-252.27M	-153.76M	40.76M	11.10M	-8.32M	-18.98M
Net Income	-713.41M	235.24M	-535.98M	-703.49M	-418.78M	-554.13M	-715.08M	-361.92M
Income Tax Expense	11.19M	25.54M	15.88M	13.53M	-168K	1.06M	1.20M	-692K
Net Profit Margin	-32.5%	12.4%	-43.1%	-75.4%	-59.7%	-102.6%	-187.8%	-120.2%
EBITDA	-613.25M	255.81M	-223.43M	-494.34M	-421.69M	-524.42M	-681.06M	-331.38M
EBITDA Margin	-27.9%	13.4%	-18.0%	-53.0%	-60.1%	-97.1%	-178.8%	-110.1%
Depreciation & Amortization	44.52M	37.72M	44.40M	41.86M	38.02M	39.74M	24.50M	12.24M
EPS Basic	-7.13	2.47	-5.80	-8.03	-5.15	-7.11	-9.71	-5.46
EPS Diluted	-7.13	2.34	-5.80	-8.03	-5.15	-7.11	-9.71	-5.46
Weighted Average Basic Shares	104.79M	95.08M	92.40M	87.56M	81.26M	77.96M	73.61M	66.25M
Weighted Average Diluted Shares	104.79M	107.88M	92.40M	87.56M	81.26M	77.96M	73.61M	66.25M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.